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Effect of inhibitors of histone deacetylase on the induction
of cell differentiation in murine and human erythroleukemia
cell lines
Sybille Witticha, Hans Scherfb, Changping Xieb, Birgit Heltwega,
Franck Dequiedtc,d, Eric Verdind, Clarissa Gerha¨userb and Manfred Junga
Histone deacetylase (HDAC) inhibitors are a novel class of
promising anti-cancer agents. Little information is available
on the capacity of structurally different HDAC inhibitors to
induce terminal cell differentiation in different cell types in
relation to enzyme inhibition and subtype selectivity.
Consequently, the aim of this study was to provide
a comprehensive comparison of these effects. New
biarylalanine inhibitors of HDAC were synthesized and
compared to a series of standard inhibitors from different
laboratories. Chromatographically purified rat liver and
immunoprecipitated FLAG-tagged recombinant human
HDACs were used as sources of HDAC activity. Enzyme
inhibition was studied using a fluorescent substrate and its
conversion was monitored by high-performance liquid
chromatography. The ability to induce cell differentiation
was compared in murine (Friend DS-19) and human (K562)
erythroleukemic cell lines, and was quantified by benzidine
staining. Inhibition of cell proliferation was evaluated by
cell counting. All HDAC inhibitors were identified as potent
inhibitors of erythroleukemic cell proliferation. However, we
observed a complex pattern of differentiation induction:
structurally similar inhibitors resulted in disparate activity
profiles, whereas similar profiles were detected within
distinct structural classes. Among the newly synthesized
biarylalanine compounds, a 30-methoxy derivative was
identified as a very effective inducer of terminal cell
differentiation. We conclude that investigation of subtype
selectivity of selected HDAC inhibitors does not provide a
clear link between selectivity and the observed cellular
activity profile. The predictive value of in vitro HDAC
inhibition assays for identifying anti-proliferative
compounds has been emphasized. Anti-Cancer Drugs
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Introduction
Histone deacetylase (HDAC) inhibitors are a relatively
new class of potential drugs for the treatment of
hyperproliferative, as well as parasitemic diseases [1,2].
Inhibition of HDAC leads to hyperacetylation of chro-
matin which is usually associated with transcriptional
activation of a number of genes [3,4]. One of the
important downstream events of histone hyperacetylation
is increased expression of the cyclin-dependent kinase
(cdk) inhibitory protein p21/WAF1/CIP1 resulting in cell
cycle arrest [5]. The dysregulated recruitment of HDACs
by oncogenic fusion proteins was identified as a general
mechanism for the pathogenesis of leukemia [6,7].
Therefore, HDAC is viewed as an attractive target for
anti-cancer drug development [8,9]. There are 11
subtypes known for the ‘classical’ zinc-dependent
HDACs [10], but little is known about the subtype
selectivity of established inhibitors or the biological
consequences of such an inhibition.
We had previously proposed a general model for HDAC
inhibitors that was derived from the potent natural
product inhibitors trapoxin B (TPX) and trichostatin A
(TSA) [11], and had accordingly developed the first
simple potent inhibitors of HDAC [12]. Structure–
activity studies have led to the improved inhibitor BIP1
with a biphenylalanine instead of a phenylalanine moiety
[13]. Here, we present a set of substituted biphenylala-
nines BIP2–6 that were synthesized in order to elucidate
whether HDAC inhibitory activity is dependent on
electronic properties in the biaryl moiety. We report in
vitro inhibition of rat liver HDAC activity as well as anti-
proliferative and differentiation-inducing effects in mur-
ine Friend leukemic cells (MELC) and the human K562
cell line. We also present a comparison of a series of
structurally diverse standard HDAC inhibitors in these
two erythroleukemic cell lines. Finally, selected inhibitors
were tested for their subtype selectivity concerning
HDACs 1, 3 and 6.
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Materials and methods
Chemicals
For further modification of our biphenylalanine lead
compound we used the strategy that was used previously
for similar analogs [13]. As a new route for structural
variations within this strategy 4-bromophenylalanine
methyl ester was converted to a building block with a
trityl-protected hydroxamate function that was success-
fully subjected to palladium-mediated biaryl coupling.
This resulted in substituted biphenylalanines which were
deprotected with trifluoroacetic acid/triethylsilane in
order to obtain the desired hydroxamic acids BIP2–6
(see Fig. 1). We have used boronic acids as the
electrophilic coupling partners and Pd(OAc)2/P(o-tol)3
as the catalyst. The biaryls were isolated with yields
ranging from 43 to 80%. This catalytic system has
been used previously for the synthesis of biarylalanine-
containing di- and tripeptides [14]. Purity and identity
were assured using IR and NMR spectroscopy as well
as elemental analyses. TSA, Scriptaid, SAHA and
MS275 were purchased from EMD Biosciences
(San Diego, CA). MD85 [12,15], M344, M360 [16] and
BIP1 [13] were synthesized according to the literature.
M344 is also commercially available (Alexis, Lausen,
Switzerland or EMD Biosciences: histone deacetylase
inhibitor III).
In vitro enzyme inhibition
Rat liver HDAC was partially purified essentially as
described earlier [17,18]. An ammonium sulfate precipi-
tation step was included for further purification prior to
chromatography [19]. This preparation is commercially
available (EMD Biosciences or Alexis). For testing, stock
solutions of the inhibitors (1mg/ml in ethanol for TSA
and 12mM in DMSO for all other inhibitors) were
diluted with enzyme buffer (15mM Tris–HCl, pH 7.9,
0.25mM EDTA, 10mM NaCl, 10% (v/v) glycerol, 10mM
2–mercaptoethanol).
The assay was performed as described earlier [20].
Briefly, 12 ml of a solution of the substrate (4.682mg/ml
in ethanol) and 24 ml of a solution of the internal standard
7-hydroxycoumarin (3.66mg/ml DMSO) were combined
and brought to a total volume of 1ml with enzyme buffer.
An aliquot of 10 ml of this stock solution was added to a
mixture of 100 ml (approximately 90U/ml; 1U: 1 pmol/
min) of rat enzyme preparation (at 41C) and 10 ml of
inhibitor dilution. After 15min at 41C the mixture was
incubated for 90min at 371C. Then, the reaction was
stopped by addition of 72 ml of 1M HCl/0.4M sodium
acetate and 800 ml of ethyl acetate. After centrifugation
(10 000 g, 5min), 200 ml of the upper phase was dried
under a stream of nitrogen. The residue was dissolved in
600 ml of the chromatography eluent and 20 ml was
injected via an autosampler onto the high-performance
liquid chromatography (HPLC) system. In a modification
of the previously published assay [17,18,20], 10.5 mM
substrate was used here instead of 3.5 mM, resulting in
increased precision (data not shown). The amount of
remaining substrate was calculated relative to the
substrate control incubated without enzyme (each as
quotient of the peak area of the substrate divided by the
peak area of the internal standard). A Shimadzu RF 535 was
used as fluorescence detector for HPLC and a LiChrosorb
RP 18-5mm (1253mm; Knauer, Berlin, Germany) column
was used for separation. The Biomol HDAC fluorescent
activity assay kit was used according to the manufacturer’s
instructions. FLAG-HDAC immunoprecipitation and assays
were performed as published previously [21]
Induction of terminal cell differentiation
MEL DS19 murine erythroleukemia cells (MELC) were
maintained in DMEM containing 100U/ml penicillin G
sodium and 100 mg/ml streptomycin sulfate supplemen-
ted with 10% fetal bovine serum (Greiner, Frickenhausen,
Germany) at 371C in a 5% CO2 atmosphere. K562 human
erythroleukemia cells (obtained from the Tumorbank,
German Cancer Research Center, Heidelberg, Germany)
were maintained in RPMI medium containing 100U/ml
penicillin G sodium and 100 mg/ml streptomycin sulfate
supplemented with 10% fetal bovine serum (Greiner) at
371C in a 5% CO2 atmosphere. To test compounds for
potential to induce cell differentiation, log-phase cells
were used. Serial dilutions of compounds were prepared
in 24-well plates (Falcon) using 1ml medium/well. If
compounds were dissolved in DMSO, control wells
contained the same amount of solvent (generally 2 ml/ml
medium, 0.1% final concentration). Subsequently, the
cell suspension was added to the wells (1ml/well, 2104
cells/ml; final cell concentration 1104 cells/well). After
72 (MELC) or 96 h (K562), respectively, the experiment
was evaluated. Cell numbers were counted using a Casy 1
TTC flow cytometer (Scha¨rfe System, Reutlingen,
Germany). The proliferation of treated cells was ex-
pressed as percent proliferation in comparison with the
solvent control.
Differentiated K562 and Friend leukemic cells accumu-
late hemoglobin. Therefore, the induction of cell
differentiation was determined by benzidine staining
according to the literature [22]. To 50 ml of cells
suspension, an equal volume of benzidine solution
(2mg/ml in 0.5M acetic acid containing 2% H2O2) was
added. Within 5min the hemoglobin-containing cells
stain blue. Benzidine-positive and -negative cells were
counted under the microscope in a hemocytometer, and
the percentage of positive cells was calculated. All
compounds were first tested at 10 and 50 mM final
concentrations. According to the activity/toxicity profile,
a range of concentration was chosen for a dose–response
analysis. In selected cases, dose–response experiments
were repeated at the same concentrations and deviations
were below 5%.
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Histone hyperacetylation
K562 cells (1 105 cells/ml in 20ml) were incubated in
RPMI for 24 h and then treated with BIP6 (1.56 mM) or
MS275 (0.625 mM), respectively, for 12 h. Control cells
obtained DMSO (0.1% final concentration). Isolation of
histones, quantification of protein and acid–urea–Triton




The series of biarylalanine compounds BIP1–5 was tested
for inhibition of a partially purified rat liver HDAC
employing the fluorogenic substrate developed in
our group [17,18] and enzyme inhibitory properties
were compared. The substituents of these novel de-
rivatives were selected in order to determine with a
limited number of compounds whether inhibitory activity
was dependent on electronic properties of the aromatic
ring [24].
As BIP1 was the most potent inhibitor (see Table 1),
an unfavorable steric repulsion in the 40-position of
the substituted compounds BIP2–5 was assumed.
For substituted derivatives, the activity increased
from BIP2 to BIP5, indicative for a beneficial effect
of electron-donating substituents. Consequently, the
30-methoxy analog BIP6 was synthesized, but this
compound again was less active than the most qpotent
parent compound BIP1 (see Table 1). For comparison,
we included several standard HDAC inhibitors from
our and other labs. We investigated TSA [25],
the trichostatin analogs MD85 [12,15], M344 and
M360 [16] that were synthesized previously in our
group, Scriptaid [26], the so-called hybrid polar drug
SAHA [27] which is in clinical trials, and the benzamide
MS275 [28,29] (see Fig. 1). All IC50 values summarized
in Table 1 (except for MS275) were determined
under identical assay conditions. In contrast to published
data, we could not detect inhibitory activity of
MS275 using our methodology [30] or the commercially
available Biomol kit. A similar lack of inhibition has been
reported recently [31] and it was speculated by that
group that in vitro inhibition by MS275 is dependent on


















































MD85: n = 5, M344: n = 6, M360: n = 7
(CH2)n
BIP
1: R = -H
2: R = 3-Cl, 4-Cl
3: R = 4-Cl
4: R = 4-Me
5: R = 4-MeO
6: R = 3-MeO
Chemical structures of tested HDAC inhibitors.
Histone deacetylase inhibitors induce differentiation Wittich et al. 637
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Inhibition of proliferation and induction of terminal
differentiation
The novel HDAC inhibitors were further tested for the
anti-proliferative and differentiation-inducing potential
of murine Friend erythroleukemic cells and human K562
erythroleukemia cells. Friend cell differentiation has been
a standard model for the investigation of HDAC
inhibitors in many studies [16,32–34]. The aim of our
current studies was a comparison of effects in the murine
cell line with those in a human erythroleukemia cell line.
In addition, the above-mentioned reference inhibitors
were tested for comparative reasons. Cell differentiation
was detected by an accumulation of hemoglobin which is
easily visualized by benzidine staining. Figure 2 shows the
profiles of cellular activity, and Table 1 summarizes IC50
values for inhibition of HDAC and cellular proliferation.
All HDAC inhibitors demonstrated dose-dependent
inhibition of cell proliferation in both leukemic cell lines.
Overall, the K562 cell line was more sensitive to the
growth inhibitory potential of the test compounds than
the Friend cell line and all compounds except Scriptaid
were more toxic for the human cell line. We noticed that
IC50 values from the HDAC in vitro test were of the same
order of magnitude as the ones obtained in the anti-
proliferative tests. The biggest differences were seen
with Scriptaid, which was more than 100-fold less potent
in the cellular systems. TSA was identified as the most
potent compound in all three assays, but the unsubsti-
tuted biarylalanine BIP1 was equally effective in the
human K562 cell line.
For the induction of terminal cell differentiation, the
compounds can be arranged in three groups depending on
the maximum percentage of benzidine-positive cells. In
the Friend cell line, weak induction (less than 30%
benzidine-positive cells) was monitored with the first
group, the halogenated biaryls BIP2 and BIP3, the
trichostatin analogs MD85 and M360, Scriptaid, and
MS275. BIP2, MD85 and Scriptaid were weak inducers in
the K562 cell line as well. The second group, consisting of
the methyl biaryl BIP4, its methoxy analogs BIP5 and
BIP6, TSA, and SAHA, showed a moderate differentia-
tion induction potential in 30–50% of the surviving Friend
cells. The percentage of benzidine-positive cells for BIP4
was similar in K562 cells. BIP5 was less effective in the
human cell line, whereas SAHA, MS275 and the 30-
methoxy compound BIP6 were identified as potent
inducers of differentiation in K562 cells (above 50%).
The unsubstituted biarylalanine BIP1 and the amino-
heptanoate analog of TSA (M344) were found to most
potently induce terminal cell differentiation in Friend
cells (above 50%) which was reduced somewhat for BIP1
and strongly (below 30%) for M344 in the human cell
line.
Histone hyperacetylation
With compound BIP6 and the reference compound
MS275 we additionally investigated the potential to
induce hyperacetylation in K562 cells by AUT gel
electrophoresis as described in the literature [22,23]. As
outlined above, both compounds belong to the most
potent group to induce differentiation in K562 cells. Both
compounds led to accumulation of hyperacetylated
histone H4 when K562 cells were treated for 12 h
with 1.56 mM BIP6 or with 0.625 mMMS275, respectively
(Fig. 3).
HDAC subtype selectivity
We have previously shown that the aminoheptanoate
M344 (good inducer of MELC differentiation) is
selective for HDAC6 (3-fold) [30]. On the other hand,
the aminooctanoate M360 (little induction of differentia-
tion) was slightly selective for HDAC1 [30] (see
Table 2). In this report, we additionally investigated the
aminocaproate MD85, and the biaryls BIP2 (little
induction of differentiation) and BIP6 (good induction
of differentiation) for inhibition of immunoprecipitated
FLAG-tagged HDAC1 and HDAC6, using a radioactively
labeled histone peptide fragment as the substrate. Data
for inhibition of HDAC3 is additionally presented for all
compounds.
Discussion
Here, we report the synthesis of novel biarylalanine
HDAC inhibitors, which do not exceed the potency of
the unsubstituted lead compound in its in vitro HDAC-
inhibitory potency. As neither electron-donating nor
electron-withdrawing substituents lead to an increase,
we assume that additional substitutions of the biaryl
Table 1 In vitro rat liver HDAC inhibition in comparison with
inhibition of cell proliferation of Friend murine and K562 human










BIP1 0.29±0.03c 0.64 0.04
BIP2 0.70±0.04 1.92 1.14
BIP3 0.53±0.03 0.46 0.31
BIP4 0.45±0.06 0.64 0.23
BIP5 0.41±0.03 0.58 0.20
BIP5 0.63±0.06 3.27 0.71
TSA 0.01±0.001d 0.04 0.05
MD85 0.22±0.02d 9.51 2.20
M344 0.12±0.01d 1.00 0.34
M360 0.20±0.02 3.97 1.80
Scriptaid 0.06±0.02d 9.30 11.8
SAHA 0.17±0.03d 0.89 0.61
MS275 NIe/4.8f/130±18g 1.24 0.31
Referenced inhibition data (except note f) was generated in our laboratory under
identical conditions.
aMean values of half-maximal inhibitory concentrations (IC50) ±SD were
computed from four experiments.
bIC50 values were generated from testing six to eight concentrations in duplicate.
cData taken from [13].
dData taken from [19].
eNo inhibition at 100 mM.
fData taken from [29].
gData using the Biomol assay.
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moiety in BIP1 are not favorable for inhibitory activity
due to steric hindrance. Possibly, the region of the
enzyme that the biphenyl group binds to is quite
restricted in the tolerance of inhibitors. As HDAC1, in
particular, is thought to be important for mediation of
cancer cell proliferation [35] and no structural data for
that subtype is available, BIP1 might be an interesting
candidate for docking experiments in homology models of
human HDACs [36] that can be derived from the
structure of the homologous bacterial histone-deacety-
lase-like-protein (HDLP) [37] or human HDAC8 [38].
All HDAC inhibitors that were investigated in this study
were identified as strong anti-proliferative drugs in
erythroleukemic cells, which emphasizes their potential
as anti-cancer drugs. Especially interesting is the activity
Fig. 2
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(a)
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of the biphenylalanine BIP1 that is as potent as TSA in
the human erythroleukemic K562 cell line. For most
compounds the cellular activity was observed in the same
concentration range as for enzyme-inhibitory activity,
which supports the use of HDAC in vitro assays as
screening tools for drug discovery. Therefore, we and
others have also developed homogeneous assays for the
determination of HDAC activity [39,40]. The lack
of correlation with MS275 has been reported by
another group before [31]. As MS275 shows in vitro
enzyme inhibition in some papers in the low micromolar
range which we and others could not reproduce,
its activity might depend strongly on the enzyme
preparation.
Fig. 2 Continued
BIP5 MELC BIP5 K562
BIP6 MELC BIP6 K562
TSA MELC TSA K562
MD85 MELC MD85 K562
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The patterns of induction of differentiation are more
complex as the maximum levels of terminal cell
differentiation achieved in the surviving cell population
range from 0 to 68% among the various inhibitors. Not
only are there differences between structurally very
similar inhibitors in one cell type (e.g. M344 versus
M360 in Friend cells), but some of the inhibitors have
entirely different profiles of activity in the two erythro-
leukemic cell lines (e.g. M344 or MS275). The reasons
for these observations remain unclear. A HDAC subtype
selectivity of the various inhibitors is a possible explana-
tion, and docking experiments with MD85, M344
and M360 in a homology model of human HDAC1
[36] supported the possibility of such a selectivity.
Consequently, we have identified a difference in
selectivity regarding HDAC1 and HDAC6 for M344 and
M360 [30]. In this group of trichostatin analogs, stronger
inhibition of HDAC6 is associated with stronger anti-
Fig. 2 Continued
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M360 MELC M360 K562
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Scriptaid MELC
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Scriptaid K562
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SAHA MELC
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SAHA K562
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(c)
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proliferative activity and more potent induction of Friend
cell differentiation (see Fig. 2). Additionally, the HDAC6-
selective M344 is also a better inducer of g-globin
expression [41] and leads to a more pronounced radio-
sensitization of cancer cells [42]. On the other hand, in
the biaryl series, the weak inducer of differentiation
(BIP2) is selective towards HDAC6, whereas the potent
inducer (BIP6) is selective for HDAC3. TSA is unselec-
tive among the three subtypes, whereas TPX inhibits
mainly HDAC1. The weak inhibitor butyrate leads to
stronger inhibition of HDAC1 and HDAC3 (Table 2).
Larger numbers of inhibitors have to be tested on more
subtypes to further elucidate possible links between
subtype selectivity and a profile of biological activity.
A differential downstream response to the gene activation
induced by distinct inhibitors in the two cell lines may
explain the varying results between Friend and K562
cells. We have shown before that, for example, BIP1 [13]
or M344 [16] induce histone hyperacetylation at relevant
concentrations, but an interaction with additional targets
is also possible. As an example, BIP1 inhibits cell
proliferation in the K562 cell line at 7-fold lower
concentrations as compared to the inhibition in the
enzyme assay.
Conclusion
Structural variations of a biphenylalanine HDAC inhibitor
BIP1 have identified its 30-methoxy analog BIP6 as a very
good inducer of terminal cell differentiation in the K562
human erythroleukemic cell line. Compound BIP1 has an
anti-proliferative potency in K562 cells that reaches that
Fig. 2 Continued
MS275 MELC






























































Induction of terminal cell differentiation (squares and solid lines) and inhibition of proliferation (circles and dotted lines) by HDAC inhibitors in Friend
(MELC) and K562 cells. The graphs for the MELC results for TSA, MD85, M344, M360 [16], BIP1 and SAHA [13] are taken from our previous work.









−      C     MS    B6    M 
Acetylation status of histone H4 in K562 cells treated with BIP6 (B6,
1.56 mM) or MS275 (MS, 0.625mM) for 12 h. A ‘–’ represents untreated
cells, C stands for the solvent control treated with 0.1% DMSO.
Ac0–4: number of acetylated lysines. M: marker (cytochrome c). See
Materials and methods for details.










BIP2 400 310 100
BIP6 2540 790 2500
MD85 390 390 330
M344 250b 480 90b
M360 110b 410 170b
TSAc 2–6 2 9
TPXc 0.1–10 100 360
Butyratec 0.1mM 0.1mM 6mM
aMean values of half-maximal inhibitory concentrations (IC50) were generated
from testing four to six concentrations in duplicate.
bData taken from [30].
cData taken from [43,44].
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of the benchmark TSA. Based on these results, further
modifications of its structure besides 30- or 40-substitu-
tion are planned. The first comprehensive comparison of
standard HDAC inhibitors in two cellular differentiation
models further reveals striking differences among the
various inhibitors and in the action of some of the
inhibitors on different cell lines. This will stimulate
mechanistic studies aimed at the elucidation of the
molecular basis of action of these promising drug
candidates. So far there is no clear link between HDAC
subtype selectivity and good induction of differentiation.
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